SEC Form 4 · accession 0000899243-18-030319
MyoKardia Inc · MYOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
June Lee
Officer — See Remarks
Period of report
Oct 31, 2018
Accepted (ET)
Dec 6, 2018 · 8:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001552451
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 31, 2018 | A | 344 | $42.16 | A | 770 | D | |
| Common Stock | Dec 3, 2018 | M | 5,000 | $11.95 | A | 5,770 | D | |
| Common StockF3 | Dec 3, 2018 | S | 2,800 | $60.077 | A | 2,970 | D | |
| Common StockF4 | Dec 3, 2018 | S | 1,200 | $61.0711 | A | 1,770 | D | |
| Common StockF5 | Dec 3, 2018 | S | 800 | $62.2586 | A | 970 | D | |
| Common Stock | Dec 3, 2018 | S | 200 | $63.76 | A | 770 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $11.95 | Dec 3, 2018 | M | 5,000 | D | — | Jan 31, 2027 | Common Stock | 5,000 | 140,000 | D |
Explanation of responses
- F1Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan.
- F2This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F3Represents the weighted average sale price of the shares sold ranging from $59.58 to $60.54 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F4Represents the weighted average sale price of the shares sold ranging from $60.89 to $61.32 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F5Represents the weighted average sale price of the shares sold ranging from $62.11 to $62.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F625% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Remarks
Chief Operating Officer and Chief Development Officer